An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT03338790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: nivolumab
DRUG: docetaxel
DRUG: enzalutamide
DRUG: rucaparib
DRUG: prednisone

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]